On the 26th, Chief Executive Officer Lim Jeong-bae of Daesang said, "We are proactively pursuing a companywide AI transformation to preemptively respond to the management environment of disruptive innovation and hyper-uncertainty sparked by the rise of artificial intelligence (AI) technology."
In greetings at the 72nd regular shareholders meeting held at Jongno Place in Jongno District, Seoul, on the same day, CEO Lim said, "Daesang is not resting on its current performance but is building a solid framework for a bigger leap forward," and stated accordingly.
CEO Lim added, "As a core prerequisite task, we are upgrading data architecture and governance to organize high-quality data," and "By embedding the latest AI technologies across the entire business value chain, we aim to establish a data-driven decision-making system," he said.
He added, "An enterprise-wide digital constitution upgrade will become a powerful driving force that maximizes the organization's operational efficiency, secures agility in response to market changes, and elevates our fundamental competitiveness to the next level."
In particular, CEO Lim emphasized the performance of the specialty business. He said, "In our specialty business, which is our core future growth engine, we also reaped valuable results," and "With the recent successful completion of the acquisition of Germany's Amino, we have taken a step forward to become a global bio corporations leading the high value-added pharmaceutical amino acid market beyond traditional food and ingredients."
Meanwhile, at the shareholders meeting that day, Daesang approved all major agenda items as originally proposed, including: ▲ approval of financial statements ▲ partial amendments to the articles of incorporation ▲ appointment of directors and audit committee members ▲ approval of the limit on directors' remuneration.